People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Elixirgen Therapeutics, Inc. | — | Biotechnology | Series A | $34.1M | $11.1M | 2023 |
Jeffrey K. Cleland at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey K. Cleland on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas White | 1 | 5 |
| JEFFREY CLELAND | 1 | 4 |
| SHAUNA CALLAHAN | 1 | 2 |
| AKIHIRO KO | 1 | 1 |
| Akihiro C Ko | 1 | 1 |
| Minoru S.H. Ko | 1 | 1 |
| Hiroaki C Kobayashi | 1 | 1 |
| Thomas K. White | 1 | 1 |
| Shauna K. Callahan | 1 | 1 |
| Maiko Katadae | 1 | 1 |
| Naonori Kurokawa | 1 | 1 |
| HIROAKI KOBAYASHI | 1 | 1 |
| MINORU KO | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.